
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. has demonstrated strong financial performance, evidenced by a 30% growth in placements for its Voyager earn-out program and a 5% revenue growth in US spinal fixation. The company reported an overall top line increase of 10% in its global spine business, with 8% revenue growth in US limb reconstruction, highlighting the effectiveness of its cross-selling strategies and optimization of its distributor network, which saw its top 30 US distributor partners grow by 25%. Additionally, Orthofix generated a robust free cash flow of $16.8 million for the quarter and anticipates maintaining positive free cash flow throughout 2026, indicating a solid financial position and a capacity for sustained growth.
Bears say
Orthofix Medical Inc. displayed a disappointing forward guidance for fiscal years 2026 and 2027, with a delay in achieving its long-term adjusted EBITDA margin target to 2028, which has contributed to a negative outlook on its stock. Although the company reported a revenue beat of $219.9 million for the quarter, the shortfall in spinal implants and biologics, along with challenges from a distributor transition, raised concerns about the sustainability of growth in its core Global Spine segment. Furthermore, despite GAAP SG&A expenses being slightly lower than anticipated at 62.2% of revenue, underlying issues such as weak placements in 7D Flash Navigation and softness in biologics have tarnished expectations for future performance.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares